Inalacor (Fluticasone Propionate)

Fluticasone propionate binds to glucocorticoid receptors inside airway cells, forming a complex that moves into the nucleus and influences gene transcription. This action suppresses the production of inflammatory cytokines, chemokines and adhesion molecules, leading to decreased recruitment of eosinophils and other inflammatory cells, thereby reducing airway edema and hyper‑responsiveness.

The dose of Inalacor is individualized by the prescribing clinician based on the severity of the patient’s asthma or COPD, age, and response to therapy. The prescriber determines the number of inhalations per day and may adjust the regimen during follow‑up visits to achieve optimal control while using the lowest effective dose.

Safety data for inhaled fluticasone propionate in pregnancy and lactation are limited. The medication should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers usually assess each case and may consider alternative therapies when appropriate.

To place an order, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Inalacor delivers fluticasone propionate, which has high topical potency and low systemic bioavailability compared with some other inhaled steroids such as budesonide. This profile allows effective anti‑inflammatory control at relatively low inhaled doses, potentially reducing the risk of systemic side effects while providing comparable efficacy in asthma and COPD maintenance.

Inalacor should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and direct sunlight. Keep the inhaler device upright, avoid exposing it to extreme temperatures, and discard any unit that appears damaged or past its expiration date.

Inalacor is delivered via a metered‑dose inhaler. The patient should exhale fully, place the mouthpiece in the mouth, seal lips around it, and press the canister while inhaling slowly and deeply. After each actuation, the patient should hold their breath for about 10 seconds before exhaling gently. Proper technique should be reviewed regularly.

The most serious adverse events include adrenal suppression, which can lead to inadequate stress response; pneumonia, particularly in COPD patients; and paradoxical bronchospasm, a sudden worsening of airway obstruction after inhalation. Patients should be instructed to seek immediate medical attention if they experience severe shortness of breath, unusual fatigue, or signs of infection.

Inalacor is contraindicated in individuals with a known hypersensitivity to fluticasone propionate or any of the inhaler’s excipients. It should also be avoided in patients with active, untreated tuberculosis or other severe infections of the respiratory tract, as the drug’s immunosuppressive effect may exacerbate these conditions.